Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Study sponsor: Genelux Corporation
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2027-02Estimated
Enrollment · participants142Estimated
Source updated2026-06-04Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.